Physician profile
Ryan Shilian
NPI 1598144032
$2,091.34
in general payments reported to CMS, 2019-2025
26 companies · $470 in 2025
The $470 reported for 2025 was less than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2020: $326 · 2021: $365 · 2022: $357 · 2023: $117 · 2024: $313 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $899.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $308.69 | 2019-2025 | |
| Glaxosmithkline, LLC. | $296.61 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $171.20 | 2021-2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $139.75 | 2021-2024 | Takhzyro |
| Optinose US, INC. | $120.06 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $117.44 | 2020-2025 | Tezspire |
| Biocryst US Sales Co., LLC | $97.16 | 2022-2025 | Orladeyo |
| Octapharma USA, INC. | $95.92 | 2024-2025 | Cutaquig, Panzyga, Octagam Immune Globulin (Human) |
| Grifols USA, LLC | $87.78 | 2022 | |
| Genzyme Corporation | $76.54 | 2020-2024 | |
| Pharming Healthcare, INC. | $62.60 | 2019-2022 | |
| Ionis Pharmaceuticals, INC. | $58.72 | 2025 | Dawnzera |
| Pfizer INC. | $53.73 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.46 | 2021-2022 | |
| Ars Pharmaceuticals Operations, INC. | $53.01 | 2025 | Neffy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $51.02 | 2020 | |
| Horizon Therapeutics Plc | $49.46 | 2020-2021 | |
| Greer Laboratories, INC. | $29.76 | 2025 | Oralair |
| Amgen INC. | $26.20 | 2021 | |
| Aimmune Therapeutics, INC. | $24.45 | 2022 | |
| Arcutis Biotherapeutics, INC. | $23.94 | 2025 | Zoryve |
| Abbvie INC. | $22.68 | 2021 | |
| Phadia US INC. | $20.28 | 2024 | Immunocap |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.26 | 2025 | Lifevest |
| Genentech USA, INC. | $18.57 | 2021 | |
| Eyevance Pharmaceuticals LLC | $13.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Shilian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.